摘要
目的探讨血清胸苷激酶1(TK1)与非小细胞肺癌(NSCLC)临床分期及病理类型的关系。方法采用免疫印迹增强化学发光法检测49例NSCLC患者血清TK1的浓度。其中,腺癌33例,鳞癌16例。结果鳞癌患者血清TK1浓度高于腺癌患者[(3.63±1.15)pmol/L vs.(2.58±1.01)pmol/L](P<0.05)。临床分期Ⅲ+Ⅳ期NSCLC患者血清TK1浓度高于Ⅰ+Ⅱ期患者(P<0.05)。血清TK1浓度与是否有淋巴结转移及肿瘤分化程度之间无明显相关性(P>0.05)。结论术前检测NSCLC患者血清TK1浓度对判断肿瘤临床分期及病理类型有重要的临床意义。
Objective To analyze the relationship between serum thymidine kinase 1(TK1)and tumor stages and pathological types in the patients with non-small cell lung cancer(NSCLC).Methods Serum TK1 was determined by enhanced chemiluminescence assay(ECLA)in 49 patients with NSCLC,of whom 16 cases were with squamous cell lung cancer(group A)and 33 cases were with lung adenocarcinoma(group B).Results Serum TK1 was higher in group A than that in group B[(3.63±1.15)pmol/L vs.(2.58±1.01)pmol/L](P〈0.05).Serum levels of TK1 were significantly higher in the patients with stagesⅢ+Ⅳ of NSCLC than those with stagesⅠ+Ⅱ(P〈0.05).Serum levels of TK1 were not significantly correlated to lymph node metastasis or tumor differentiation(P〉0.05).Conclusion Detection of serum TK1 before operation has an important clinical significance in evaluating the tumor clinical stages and pathological types in the patients with NSCLC.
出处
《江苏医药》
CAS
北大核心
2014年第21期2555-2557,共3页
Jiangsu Medical Journal
关键词
胸苷激酶1
非小细胞肺癌
Thymidine kinase 1
Non-small cell lung cancer